IL327005A - מעכבי דיהידרופיראנופירידיןkras ספירוציקליים - Google Patents
מעכבי דיהידרופיראנופירידיןkras ספירוציקלייםInfo
- Publication number
- IL327005A IL327005A IL327005A IL32700526A IL327005A IL 327005 A IL327005 A IL 327005A IL 327005 A IL327005 A IL 327005A IL 32700526 A IL32700526 A IL 32700526A IL 327005 A IL327005 A IL 327005A
- Authority
- IL
- Israel
- Prior art keywords
- kras
- mutant protein
- compound
- group
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363539749P | 2023-09-21 | 2023-09-21 | |
| US202363614278P | 2023-12-22 | 2023-12-22 | |
| US202463559588P | 2024-02-29 | 2024-02-29 | |
| US202463567238P | 2024-03-19 | 2024-03-19 | |
| US202463650239P | 2024-05-21 | 2024-05-21 | |
| US202463653043P | 2024-05-29 | 2024-05-29 | |
| US202463675512P | 2024-07-25 | 2024-07-25 | |
| US202463685160P | 2024-08-20 | 2024-08-20 | |
| PCT/US2024/047734 WO2025064848A1 (en) | 2023-09-21 | 2024-09-20 | Spirocyclic dihydropyranopyridine kras inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL327005A true IL327005A (he) | 2026-05-01 |
Family
ID=92966945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL327005A IL327005A (he) | 2023-09-21 | 2024-09-20 | מעכבי דיהידרופיראנופירידיןkras ספירוציקליים |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4780823A1 (he) |
| KR (1) | KR20260074662A (he) |
| CN (1) | CN121889400A (he) |
| AU (1) | AU2024344161A1 (he) |
| IL (1) | IL327005A (he) |
| MX (1) | MX2026003472A (he) |
| TW (1) | TW202528315A (he) |
| WO (1) | WO2025064848A1 (he) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5922720B2 (ja) | 2014-07-31 | 2016-05-24 | 株式会社コナミデジタルエンタテインメント | ゲームシステム、それに用いられる制御方法及びコンピュータプログラム |
| WO2016077793A1 (en) | 2014-11-14 | 2016-05-19 | Children's Hospital Medical Center | Sos1 inhibitors for cancer treatment |
| WO2016161361A1 (en) | 2015-04-03 | 2016-10-06 | Nantbioscience, Inc. | Compositions and methods of targeting mutant k-ras |
| AU2016245864C1 (en) | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| KR102218333B1 (ko) | 2016-06-07 | 2021-02-22 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| IL311645B2 (he) | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5-דימותמרים 3- מתיל פיראזינים ו- 2,5,6- תלתמותמרים 3- מתיל פיראזינים כמעכבים ל shp2 אלוסטריים |
| EP3269365A1 (en) | 2016-07-14 | 2018-01-17 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Kras inhibitor for use in treating cancer |
| EP3558979B1 (en) | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| UA127968C2 (uk) | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| CA3082579A1 (en) | 2017-11-15 | 2019-05-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| PL3728254T3 (pl) | 2017-12-21 | 2023-06-12 | Boehringer Ingelheim International Gmbh | Benzyloaminopodstawione pirydopirymidynony i pochodne jako inhibitory sos1 |
| WO2019152454A1 (en) | 2018-01-30 | 2019-08-08 | Research Development Foundation | Shp2 inhibitors and methods of use thereof |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
| RU2020133727A (ru) | 2018-03-21 | 2022-04-21 | Сучжоу Пухе Биофарма Ко., Лтд. | Ингибиторы shp2 и их применение |
| CN112119075B (zh) | 2018-08-16 | 2024-03-12 | 豪夫迈·罗氏有限公司 | 稠环化合物 |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| WO2020097537A2 (en) | 2018-11-09 | 2020-05-14 | Genentech, Inc. | Fused ring compounds |
| US20230096028A1 (en) | 2019-03-01 | 2023-03-30 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| CA3141604A1 (en) | 2019-05-20 | 2020-11-26 | 1200 Pharma Llc | Kras g12c inhibitors and uses thereof |
| CN114615981B (zh) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| MD4051678T2 (en) | 2019-10-28 | 2026-07-31 | Merck Sharp & Dohme Llc | Small molecule inhibitors of the KRAS G12C mutant |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| PH12022551102A1 (en) | 2019-11-08 | 2023-11-20 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof |
| WO2021093758A1 (zh) | 2019-11-15 | 2021-05-20 | 四川海思科制药有限公司 | 一种嘧啶并环衍生物及其在医药上的应用 |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| WO2021104431A1 (zh) | 2019-11-29 | 2021-06-03 | 苏州信诺维医药科技股份有限公司 | Kras g12c抑制剂化合物及其用途 |
| WO2021113595A1 (en) | 2019-12-06 | 2021-06-10 | Beta Pharma, Inc. | Phosphorus derivatives as kras inhibitors |
| MX2022007051A (es) | 2019-12-10 | 2022-12-06 | Univ Texas | Composiciones y metodos para analogos de 7-(piperazin-1-il)pirazol o[1,5-a]pirimidina sustituidos como inhibidores de kras. |
| CR20220258A (es) | 2019-12-11 | 2022-07-03 | Lilly Co Eli | Inhibidores de kras g12c |
| WO2021120890A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| WO2021139748A1 (en) | 2020-01-08 | 2021-07-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Spirocyclic tetrahydroquinazolines |
| WO2021142252A1 (en) | 2020-01-10 | 2021-07-15 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| WO2022115439A1 (en) | 2020-11-25 | 2022-06-02 | California Institute Of Technology | Kras g12c inhibitors and uses thereof |
| EP4262807A4 (en) * | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| CN114685502A (zh) | 2020-12-25 | 2022-07-01 | 由理生物医药（上海）有限公司 | 作为kras-g12c抑制剂的螺环类化合物 |
| AU2022220678A1 (en) | 2021-02-09 | 2023-09-21 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| CA3215949A1 (en) | 2021-04-08 | 2022-10-13 | Genentech, Inc. | Oxazepine compounds and uses thereof in the treatment of cancer |
| WO2022236578A1 (en) | 2021-05-10 | 2022-11-17 | Nikang Therapeutics, Inc. | Exocyclic amino quinazoline derivatives as kras inhibitors |
| WO2022240971A2 (en) | 2021-05-11 | 2022-11-17 | 1200 Pharma Llc | Kras g12d inhibitors and uses thereof |
| BR112023024906A2 (pt) | 2021-05-28 | 2024-02-15 | Redx Pharma Plc | Compostos |
| CN117769554A (zh) | 2021-05-28 | 2024-03-26 | 大鹏药品工业株式会社 | Kras突变蛋白的小分子抑制剂 |
| EP4347606A4 (en) | 2021-05-28 | 2025-04-02 | Merck Sharp & Dohme LLC | SMALL MOLECULES INHIBITING THE G12C KRAS MUTANT |
| WO2022256459A1 (en) | 2021-06-01 | 2022-12-08 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| CN117500799A (zh) | 2021-06-09 | 2024-02-02 | 伊莱利利公司 | 作为kras g12d抑制剂的取代的稠合吖嗪 |
| WO2022258974A1 (en) | 2021-06-10 | 2022-12-15 | Redx Pharma Plc | Quinazoline derivatives useful as ras inhibitiors |
| CA3221608A1 (en) | 2021-06-14 | 2022-12-22 | Kumquat Biosciences Inc. | Fused heteroaryl compounds useful as anticancer agents |
| WO2023284881A1 (en) | 2021-07-16 | 2023-01-19 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds useful as kras g12d inhibitors |
| CN116143806A (zh) | 2021-08-08 | 2023-05-23 | 上海凌达生物医药有限公司 | 一类含氮杂环类化合物、制备方法和用途 |
| WO2023018812A1 (en) | 2021-08-10 | 2023-02-16 | Amgen Inc. | Heterocyclic compounds and methods of use |
| JP2024532735A (ja) | 2021-08-10 | 2024-09-10 | アムジエン・インコーポレーテツド | 複素環式化合物及び使用方法 |
| US20240417412A1 (en) | 2021-08-10 | 2024-12-19 | Amgen Inc. | Heterocyclic compounds and methods of use |
| WO2023020519A1 (en) | 2021-08-18 | 2023-02-23 | Jacobio Pharmaceuticals Co., Ltd. | 1, 4-oxazepane derivatives and uses thereof |
| WO2023020521A1 (en) | 2021-08-18 | 2023-02-23 | Jacobio Pharmaceuticals Co., Ltd. | Pyridine fused pyrimidine derivatives and use thereof |
| WO2023020518A1 (en) | 2021-08-18 | 2023-02-23 | Jacobio Pharmaceuticals Co., Ltd. | N-cyclopropylpyrido [4, 3-d] pyrimidin-4-amine derivatives and uses thereof |
| WO2023020523A1 (en) | 2021-08-18 | 2023-02-23 | Jacobio Pharmaceuticals Co., Ltd. | Bicyclic derivatives and use thereof |
| WO2023025116A1 (zh) | 2021-08-25 | 2023-03-02 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| CN116284055B (zh) | 2021-09-10 | 2025-09-23 | 润佳（苏州）医药科技有限公司 | 一种kras抑制剂及其用途 |
| CN118019746A (zh) | 2021-09-27 | 2024-05-10 | 北京加科思新药研发有限公司 | 多环稠环衍生物及其用途 |
| WO2023061294A1 (zh) | 2021-10-13 | 2023-04-20 | 再鼎医药(上海)有限公司 | 含氮杂环类衍生物调节剂、其制备方法及应用 |
| CA3237274A1 (en) | 2021-11-09 | 2023-05-19 | 1200 Pharma Llc | Select kras g12c inhibitors and uses thereof |
| US20260200925A1 (en) | 2021-11-24 | 2026-07-16 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras mutated proteins |
| TW202337432A (zh) | 2021-12-01 | 2023-10-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
| TW202340208A (zh) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
| EP4441050A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CR20240233A (es) | 2021-12-01 | 2024-07-17 | Univ Vanderbilt | Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer |
| EP4442686A4 (en) | 2021-12-02 | 2025-10-22 | Abbisko Therapeutics Co Ltd | KRAS INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL USE |
| WO2023114733A1 (en) | 2021-12-13 | 2023-06-22 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| WO2023125627A1 (en) | 2021-12-28 | 2023-07-06 | Lynk Pharmaceuticals Co., Ltd. | Nitrogen-containing heterocyclic compound and application thereof |
| WO2023137223A1 (en) | 2022-01-17 | 2023-07-20 | Newave Pharmaceutical Inc. | Pan-kras inhibitors and uses thereof |
| WO2023141300A1 (en) | 2022-01-20 | 2023-07-27 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2023138583A1 (zh) | 2022-01-21 | 2023-07-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| JP2025504041A (ja) | 2022-01-30 | 2025-02-06 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | キノリン系化合物及びその使用 |
| IL314486A (he) | 2022-02-03 | 2024-09-01 | Mirati Therapeutics Inc | תרכובות קווינאזולין מעכבות pan-kras |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| JP2025508702A (ja) | 2022-02-16 | 2025-04-10 | アムジエン・インコーポレーテツド | キナゾリン化合物、及び変異ｋｒａｓタンパク質の阻害剤としてのその使用 |
| CN118715215A (zh) | 2022-02-16 | 2024-09-27 | 美国安进公司 | 作为突变kras蛋白抑制剂的喹唑啉化合物及其用途 |
| WO2023173016A1 (en) | 2022-03-09 | 2023-09-14 | Blossomhill Therapeutics, Inc. | Kras inhibitors for treating disease |
| WO2023173017A1 (en) | 2022-03-09 | 2023-09-14 | Blossomhill Therapeutics, Inc. | Kras inhibitors for treating disease |
| JP2025510656A (ja) | 2022-03-24 | 2025-04-15 | ベイジーン スウィッツァーランド ゲーエムベーハー | 複素環式化合物、その組成物、及びそれらを用いた治療方法 |
| WO2023183585A1 (en) | 2022-03-25 | 2023-09-28 | Eli Lilly And Company | Kras inhibitors |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| CN120019052A (zh) | 2022-08-05 | 2025-05-16 | 瑟拉斯有限公司 | 用于抑制kras的组合物和方法 |
| KR20250109197A (ko) | 2022-11-21 | 2025-07-16 | 트리라인 바이오사이언시스, 인크. | 스피로환식 디하이드로피라노피리미딘 KRas 억제제 |
-
2024
- 2024-09-20 WO PCT/US2024/047734 patent/WO2025064848A1/en not_active Ceased
- 2024-09-20 TW TW113135803A patent/TW202528315A/zh unknown
- 2024-09-20 KR KR1020267009440A patent/KR20260074662A/ko active Pending
- 2024-09-20 AU AU2024344161A patent/AU2024344161A1/en active Pending
- 2024-09-20 CN CN202480059817.8A patent/CN121889400A/zh active Pending
- 2024-09-20 EP EP24783541.6A patent/EP4780823A1/en active Pending
- 2024-09-20 IL IL327005A patent/IL327005A/he unknown
-
2026
- 2026-03-20 MX MX2026003472A patent/MX2026003472A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4780823A1 (en) | 2026-07-29 |
| KR20260074662A (ko) | 2026-05-26 |
| AU2024344161A1 (en) | 2026-03-26 |
| WO2025064848A1 (en) | 2025-03-27 |
| CN121889400A (zh) | 2026-04-17 |
| TW202528315A (zh) | 2025-07-16 |
| MX2026003472A (es) | 2026-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL318420A (he) | מעכבי kras | |
| IL320913A (he) | מעכבי kras דיהידרופירנופירימידין ספירוציקליים | |
| IL326518A (he) | מעכבי kras דיהידרופיראנופירימידין ספירוציקליים | |
| IL290845A (he) | מעכבי kras g12d | |
| EP4192585A4 (en) | Kras g12d inhibitors | |
| EP4322945A4 (en) | KRAS G12C INHIBITORS | |
| EP4240489A4 (en) | KRAS-G12D INHIBITORS | |
| EP4182313A4 (en) | KRAS-G12D INHIBITORS | |
| EP4216951A4 (en) | KRAS G12D INHIBITORS | |
| DK3886991T3 (da) | KRas G12C-inhibitorer | |
| IL314033A (he) | מעכבי ras | |
| EP4262803A4 (en) | Tetrahydropyridopyrimidine pan-kras inhibitors | |
| IL311840A (he) | מעכבי ras | |
| IL292643A (he) | מעכבי ras | |
| IL292644A (he) | מעכבי ras | |
| IL292642A (he) | מעכבי ras | |
| EP4069212A4 (en) | INHIBITORS OF HIF-2ALPHA | |
| EP3844151A4 (en) | KRAS G12C INHIBITORS | |
| EP3790551A4 (en) | Kras g12c inhibitors | |
| DK4337652T3 (da) | NLRP3-hæmmere | |
| IL277778B (he) | מעכבים של bcl6 | |
| IL315027A (he) | מעכבים של nlrp3 | |
| EP4038060C0 (en) | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR | |
| DK4043466T3 (da) | PRC2-inhibitorer | |
| EP4247372A4 (en) | PLASMA KALLICREIN INHIBITORS |